X

The Lancet Oncology

The Lancet Oncology
Cetuximab, Docetaxel, and Cisplatin versus Platinum, Fluorouracil, and Cetuximab as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Results from a phase 2 trial of the TPEx chemotherapy regimen show promising results, with a median overall survival of 14·0 months in first-line recurrent or metastatic HNSCC.

The Lancet Oncology
04/01/2021
MRI-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer (EMBRACE-I)

This study reports on EMBRACE-I, which aims to evaluate local tumor control and morbidity after chemoradiotherapy and MRI-based IGABT.

The Lancet Oncology
04/01/2021
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation

The aim of this final analysis is to investigate the effect of olaparib on overall survival.

The Lancet Oncology
03/18/2021
Subscribe to The Lancet Oncology

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39